<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973765</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20080055H_</org_study_id>
    <nct_id>NCT00973765</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses</brief_title>
  <official_title>Randomized Placebo-Controlled Trial of Bactrim on 7 Day Outcome in Emergency Department Patients With Uncomplicated Abscesses at Risk for Community Acquired Methicillin Resistant Staph Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilford Hall Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emergency Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wilford Hall Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be enrolled in a multi-center study to prospectively evaluate outcome after
      treatment for an uncomplicated skin abscess. All patients will receive incision and drainage
      and wound cultures. Patients will then be randomized to 1) placebo two tablets PO BID X 7
      days or 2) bactrim DS (800/160) two tablets PO BID x 7 days. Patients will then return to the
      emergency department ED) at 48 hours and 7 for wound repacking and evaluation. The primary
      outcome is treatment failure rates at 7 days after incision and drainage. Patients who are
      clinically worsening or not improving after 48 hours will then be treated with additional
      antibiotics or admission if needed. Data will be analyzed both by initial randomization and
      intention to treat.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failures at 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>worsening abscess or new recurrence of abscess</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Abscesses</condition>
  <arm_group>
    <arm_group_label>bactrim DS (800/160) 2 pills po BID x 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo 2 pills po BID x 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bactrim</intervention_name>
    <description>bactrim DS (800/160) 2 pills PO BID x 7 days</description>
    <arm_group_label>bactrim DS (800/160) 2 pills po BID x 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 2 pills po BID x 7 days</description>
    <arm_group_label>Matched placebo 2 pills po BID x 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria include all patients age 16 and older who present to the emergency
             department with a skin abscess that requires incision and drainage.

        Exclusion Criteria:

          -  Exclusion criteria include patients with diabetes, HIV, cancer or other
             immunocompromised patients.

          -  Additionally, any patients who received antibiotics within one week of presentation or
             were hospitalized in previous month will be excluded to minimize potential confounding
             variables.

          -  Pregnant and breastfeeding patients will also be excluded due to possible safety
             concerns with antibiotic treatment.

          -  Patients with abscesses on face, perirectal, or perianal regions, abscesses with known
             tracks or fistulas to deeper structures, or abscesses requiring surgical drainage in
             an operating room are excluded.

          -  Patients with fever or evidence of systemic infection

          -  Finally, patients with sulfa allergy will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wilford Hall Medical Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <results_first_submitted>January 19, 2010</results_first_submitted>
  <results_first_submitted_qc>February 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2010</results_first_posted>
  <last_update_submitted>March 1, 2010</last_update_submitted>
  <last_update_submitted_qc>March 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gillian Schmitz, MD</name_title>
    <organization>Wilford Hall Medical Center</organization>
  </responsible_party>
  <keyword>abcess</keyword>
  <keyword>MRSA</keyword>
  <keyword>cellulitis</keyword>
  <keyword>antibiotics</keyword>
  <keyword>uncomplicated abscesses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscess</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>July 1, 2008 - June 1, 2009 in emergency department</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator</title>
          <description>Bactrim DS (800/160) 2 pills po BID x 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo 2 pills po BID x 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96">96</participants>
                <participants group_id="P2" count="116">116</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88">88</participants>
                <participants group_id="P2" count="102">102</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator</title>
          <description>Bactrim DS (800/160) 2 pills po BID x 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo 2 pills po BID x 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="13.3"/>
                    <measurement group_id="B2" value="31.1" spread="12.5"/>
                    <measurement group_id="B3" value="31.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failures at 7 Days</title>
        <description>worsening abscess or new recurrence of abscess</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator</title>
            <description>Bactrim DS (800/160) 2 pills po BID x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo 2 pills po BID x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failures at 7 Days</title>
          <description>worsening abscess or new recurrence of abscess</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator</title>
          <description>Bactrim DS (800/160) 2 pills po BID x 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo 2 pills po BID x 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gillian Schmitz, MD</name_or_title>
      <organization>Washington Hospital Center</organization>
      <phone>919-724-9185</phone>
      <email>gillianmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

